- Home
- RVNC vs IKT Comparison
RVNC vs IKT Comparison
Compare RVNC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVNC
- IKT
- Stock Information
- Founded
- RVNC 1999
- IKT 2008
- Country
- RVNC United States
- IKT United States
- Employees
- RVNC N/A
- IKT N/A
- Industry
- RVNC Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- RVNC Health Care
- IKT Health Care
- Exchange
- RVNC Nasdaq
- IKT Nasdaq
- Market Cap
- RVNC 320.5M
- IKT 159.2M
- IPO Year
- RVNC 2014
- IKT 2020
- Fundamental
- Price
- RVNC $3.09
- IKT $3.42
- Analyst Decision
- RVNC Hold
- IKT Strong Buy
- Analyst Count
- RVNC 9
- IKT 2
- Target Price
- RVNC $8.45
- IKT $6.50
- AVG Volume (30 Days)
- RVNC 3.6M
- IKT 471.4K
- Earning Date
- RVNC 11-07-2024
- IKT 11-14-2024
- Dividend Yield
- RVNC N/A
- IKT N/A
- EPS Growth
- RVNC N/A
- IKT N/A
- EPS
- RVNC N/A
- IKT N/A
- Revenue
- RVNC $256,945,000.00
- IKT $1.00
- Revenue This Year
- RVNC $11.28
- IKT N/A
- Revenue Next Year
- RVNC $27.21
- IKT N/A
- P/E Ratio
- RVNC N/A
- IKT N/A
- Revenue Growth
- RVNC 25.82
- IKT N/A
- 52 Week Low
- RVNC $2.30
- IKT $1.12
- 52 Week High
- RVNC $9.75
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- RVNC 33.47
- IKT 52.41
- Support Level
- RVNC $3.06
- IKT $3.12
- Resistance Level
- RVNC $3.09
- IKT $4.20
- Average True Range (ATR)
- RVNC 0.11
- IKT 0.42
- MACD
- RVNC 0.02
- IKT -0.00
- Stochastic Oscillator
- RVNC 6.90
- IKT 30.67
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.